GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Cash, Cash Equivalents, Marketable Securities

Biosyent (Biosyent) Cash, Cash Equivalents, Marketable Securities : $19.52 Mil (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Biosyent Cash, Cash Equivalents, Marketable Securities?

Biosyent's quarterly cash, cash equivalents, marketable securities increased from Jun. 2023 ($21.02 Mil) to Sep. 2023 ($21.65 Mil) but then stayed the same from Sep. 2023 ($21.65 Mil) to Dec. 2023 ($19.52 Mil).

Biosyent's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($22.04 Mil) to Dec. 2022 ($21.12 Mil) and declined from Dec. 2022 ($21.12 Mil) to Dec. 2023 ($19.52 Mil).


Biosyent Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Biosyent's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Cash, Cash Equivalents, Marketable Securities Chart

Biosyent Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.69 19.97 22.04 21.12 19.52

Biosyent Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.12 19.18 21.02 21.65 19.52

Biosyent Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Biosyent  (OTCPK:BIOYF) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Biosyent Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Biosyent's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent (Biosyent) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Biosyent (Biosyent) Headlines

From GuruFocus

BioSyent Initiates First Dividend

By GlobeNewswire GlobeNewswire 10-12-2022

BioSyent Announces Approval of New Product

By GlobeNewswire GlobeNewswire 05-31-2023

BioSyent to Present at The LD 500 Virtual Conference

By ACCESSWIRE ACCESSWIRE 08-25-2020

BioSyent Announces Changes to Executive Management

By GlobeNewswire GlobeNewswire 09-10-2018

BioSyent Announces Grant of Restricted Share Units

By GlobeNewswire GlobeNewswire 03-31-2023

BioSyent Announces Adoption of Restricted Share Unit Plan

By GlobeNewswire GlobeNewswire 03-06-2020

BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022

By GlobeNewswire GlobeNewswire 08-17-2022

When Being Certain Isn't Enough

By Thomas Macpherson Thomas Macpherson 08-30-2019